BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 32812198)

  • 21. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
    Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
    Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status.
    Xiao Y; Ma D; Ruan M; Zhao S; Liu XY; Jiang YZ; Shao ZM
    Sci Rep; 2017 Sep; 7(1):10380. PubMed ID: 28871133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
    Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
    Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
    Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
    Bharat A; Gao F; Margenthaler JA
    Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases.
    Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Tseng LM; Huang CC
    Breast Cancer Res Treat; 2023 Oct; 201(3):547-560. PubMed ID: 37470893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
    PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database.
    Chen S; Wang J; Yang L; Ji M; Chen S
    J BUON; 2021; 26(5):1991-2002. PubMed ID: 34761609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
    Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
    Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast Carcinoma.
    Riba LA; Russell T; Alapati A; Davis RB; James TA
    J Surg Res; 2019 Jan; 233():436-443. PubMed ID: 30502283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I-III MIDLC Patients.
    Lohani KR; Hoskin TL; Day CN; Yasir S; Boughey JC; Degnim AC
    Ann Surg Oncol; 2024 Feb; 31(2):936-946. PubMed ID: 37872454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.
    Stecklein SR; Shen X; Mitchell MP
    Clin Breast Cancer; 2016 Aug; 16(4):319-26. PubMed ID: 26943990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical management of lobular carcinoma from a national screening program: a retrospective analysis.
    Sharma SD; Barry M; O'Reilly EA; Kell MR
    Eur J Surg Oncol; 2015 Jan; 41(1):79-85. PubMed ID: 25441933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.